<DOC>
	<DOCNO>NCT01879020</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , pharmacokinetics pharmacodynamics TA-8995 multiple dos healthy adult male subject</brief_summary>
	<brief_title>Evaluation Safety , Tolerability , Pharmacokinetics Pharmacodynamics TA-8995 After Multiple Doses Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>Free clinically significant illness disease determine medical history , physical examination , laboratory test judge Investigator . Between 18 55 year old . Male Caucasian ethnic origin . Body mass index ( BMI ) range 19 33 kg/m² minimum weight 50 kg . Subjects BMI range 30.0 33.0 kg/m² waist measurement ≤ 91 cm . High density lipoprotein ( HDL ) C level great equal 2.59 mmol/L ( ≥ 100 mg/dL ) Screening . Abnormal Electrocardiogram ( ECG ) Screening Day 1 include QTc ≥ 430 m ( The QTcinterval calculate automatically accord Bazett 's formula . In case result ≥ 430 m , QTc additionally calculate manually use Fridericia 's formula use exclusion criterion ) . Family history long QT syndrome , hypokalaemia Torsades de Pointes Impaired endocrine , thyroid , hepatic , respiratory renal function , diabetes mellitus , coronary heart disease history psychotic illness Presence history gastrointestinal , hepatic renal disease condition know interfere absorption , distribution , metabolism excretion drug</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>MT-8995</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Cholesteryl ester transfer protein</keyword>
</DOC>